デフォルト表紙
市場調査レポート
商品コード
1796863

再生創傷ケア市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、創傷タイプ別、エンドユーザー別、地域別、競合別、2020~2030年

Regenerative Wound Care Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Wound Type, By End User, By Region and Competition, 2020-2030F


出版日
ページ情報
英文 185 Pages
納期
2~3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

再生創傷ケア市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、創傷タイプ別、エンドユーザー別、地域別、競合別、2020~2030年
出版日: 2025年08月25日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

再生創傷ケアの世界市場規模は2024年に102億7,000万米ドルで、予測期間中のCAGRは5.97%で2030年には145億4,000万米ドルに達すると予測されています。

再生創傷ケアの世界市場は、火傷、怪我、靴擦れ、潰瘍などによる創傷の発生率の増加により、著しい成長を遂げています。さらに、様々な種類の怪我や転倒の影響を受けやすい高齢者の増加が、再生創傷ケア市場の需要を増加させると予想されています。高齢者では、その他のさまざまな関連疾患のために創傷治癒プロセスが遅いため、創傷治癒を早める製品への需要が高まり、市場の成長を支えています。国連経済社会局人口部によると、65歳以上の人口は2050年までに15億4,890万人に達すると予想されています。

市場概要
予測期間 2026~2030年
市場規模:2024年 102億7,000万米ドル
市場規模:2030年 145億4,000万米ドル
CAGR:2025~2030年 5.97%
急成長セグメント 外来手術センター
最大市場 北米

市場促進要因

慢性疾患の有病率の上昇

主要市場課題

高度再生治療の高コスト

主要市場動向

創傷治療におけるスマート技術の統合

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 臨床検査分析

第6章 世界の再生創傷ケア市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別(自己幹細胞、生物学的皮膚代替物、組織/多組織プラットフォーム、胎児皮膚、再生創傷ケアデバイス、その他)
    • 創傷タイプ別(潰瘍、外科的と外傷性の傷、火傷)
    • エンドユーザー別(病院、外来手術センター、火傷ケアセンターと創傷クリニック、その他)
    • 地域別
    • 企業別(2024年)
  • 市場マップ

第7章 北米の再生創傷ケア市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米:国別分析
    • 米国
    • カナダ
    • メキシコ

第8章 欧州の再生創傷ケア市場展望

  • 市場規模・予測
  • 市場シェア・予測
    • Bタイプ別
  • 欧州:国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第9章 アジア太平洋の再生創傷ケア市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋:国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第10章 南米の再生創傷ケア市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカの再生創傷ケア市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向と発展

  • 合併と買収
  • 製品上市

第14章 ポーターのファイブフォース分析

  • 産業内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威/サービス

第14章 SWOT分析:世界の再生創傷ケア市場

第15章 競合情勢

  • DeCell Technologies Inc.
  • Avita Medical, Inc.
  • Organogenesis, Inc.
  • Histogen, Inc.
  • RenovoDerm(Nanofiber Solutions, LLC)
  • StemsysBio
  • Koninklijke DSM N.V.
  • MiMedx Group, Inc.
  • 3M Company
  • Smith & Nephew PLC

第16章 戦略的提言

第17章 調査会社について・免責事項

目次
Product Code: 14405

Global Regenerative Wound Care Market was valued at USD 10.27 billion in 2024 and is expected to reach USD 14.54 billion by 2030 with a CAGR of 5.97% during the forecast period. The global market for Regenerative Wound Care is experiencing significant growth, driven by the growing incidence of wounds caused due to burns, injuries, soars & ulcers, among others. Additionally, the growing geriatric population which is susceptible to various kinds of injuries and falls is expected to increase the demand for regenerative wound care market. In the elderly population, due to various other associated conditions the wound healing process is slow, leading to the demand for products which can bring about faster wound healing, thereby supporting market growth. According to the United Nations, Department of Economic and Social Affairs, Population Division, the number of people aged 65 years or above is expected to reach 1548.9 million by 2050.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 10.27 Billion
Market Size 2030USD 14.54 Billion
CAGR 2025-20305.97%
Fastest Growing SegmentAmbulatory Surgical Centers
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Chronic Diseases

One of the most significant drivers of the regenerative wound care market is the growing prevalence of chronic diseases, notably diabetes, obesity, and cardiovascular disorders. These conditions are known to impair wound healing due to poor circulation, reduced immune response, and other metabolic dysfunctions. Among them, diabetes mellitus is the leading cause of chronic wounds, particularly diabetic foot ulcers (DFUs), which are notoriously difficult to treat. Globally, diabetes affects over 537 million adults, and the number is expected to rise to 643 million by 2030 and 783 million by 2045, according to the International Diabetes Federation (IDF). In the U.S. alone, the CDC reports that over 37 million Americans are diabetic, and 96 million more are prediabetic. Around 15% of diabetic patients develop foot ulcers at some point in their lives, which are susceptible to infections and often require amputation if not effectively treated.

This growing burden is driving demand for advanced and regenerative wound care technologies that can stimulate healing in patients with impaired tissue regeneration. Governments are responding to this healthcare burden with public health initiatives. For instance, the CDC's National Diabetes Prevention Program focuses on early detection, lifestyle intervention, and management strategies that indirectly push for better wound care services. Moreover, the World Health Organization (WHO) has emphasized the growing need for chronic wound care as part of universal health coverage. This global health push is propelling investments in regenerative wound treatments such as stem cell therapies, extracellular matrix products, and skin grafts, especially in middle-income countries seeking to modernize their healthcare systems.

Key Market Challenges

High Cost of Advanced Regenerative Therapies

Despite the promising nature of regenerative wound care solutions, cost remains a formidable barrier to their widespread adoption. Advanced therapies such as stem cell treatments, tissue-engineered skin, and bioactive wound dressings are considerably more expensive than traditional wound care products like gauze or hydrocolloid dressings. For example, the cost of a single application of a bioengineered skin substitute can range from $500 to $3,000, and most treatments require multiple applications. This cost is particularly prohibitive in low- and middle-income countries, where health insurance coverage may be limited or non-existent.

Even in high-income nations, insurance reimbursement can be inconsistent. While programs like Medicare and Medicaid in the U.S. have approved certain products for reimbursement, coverage limitations and complex billing processes often deter hospitals from fully adopting these treatments. In many cases, patients are required to bear out-of-pocket expenses, creating disparities in access. Although governments are attempting to ease the financial burden through subsidies, value-based care models, and innovative payment structures, a lack of uniform policy across regions continues to restrict market penetration. This challenge calls for stronger public-private collaboration to make regenerative wound therapies more economically viable for healthcare systems globally.

Key Market Trends

Integration of Smart Technologies in Wound Care

A key trend in reshaping the regenerative wound care landscape is the integration of digital health and smart technologies into wound management protocols. This includes the use of wearable sensors, artificial intelligence (AI), telehealth platforms, and remote monitoring tools for real-time wound assessment. Smart bandages equipped with biosensors can monitor wound pH, temperature, and moisture levels, providing timely insights into infection risk and healing progress. AI-based diagnostic platforms can assess wounds using image processing and machine learning, reducing diagnostic variability among clinicians and enabling standardized care.

Governments are actively promoting such innovations through health technology initiatives. For instance, the UK's National Health Service (NHS) launched the Wound Care Innovation programme as part of its Long Term Plan to reduce chronic wound burden and treatment costs. Similarly, the U.S. FDA has streamlined digital health regulations via its Digital Health Center of Excellence, encouraging innovation in remote wound care management. These smart technologies not only enhance patient outcomes but also reduce the frequency of hospital visits and the associated costs of chronic wound treatment. This trend is especially relevant in the post-COVID-19 era, where remote patient management has gained acceptance as a viable method for ongoing care, particularly among the elderly and immobile patient populations. The integration of these technologies is set to transform wound care from reactive treatment to proactive management, enabling more effective and efficient care pathways for chronic wound patients.

Key Market Players

  • DeCell Technologies Inc.
  • Avita Medical, Inc.
  • Organogenesis, Inc.
  • Histogen, Inc.
  • RenovoDerm (Nanofiber Solutions, LLC)
  • StemsysBio
  • Koninklijke DSM N.V.
  • MiMedx Group, Inc.
  • 3M Company
  • Smith & Nephew PLC

Report Scope:

In this report, the Global Regenerative Wound Care Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Regenerative Wound Care Market, By Type:

  • Autologous Stem Cells
  • Biological Skin Substitutes
  • Tissue/Multiple Tissue Platform
  • Fetal Skin
  • Regenerative Wound Care Devices
  • Others

Regenerative Wound Care Market, By Wound Type:

  • Ulcers
  • Surgical & Traumatic Wounds
  • Burns

Regenerative Wound Care Market, By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Burn Care Centers & Wound Clinics
  • Others

Regenerative Wound Care Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Regenerative Wound Care Market.

Available Customizations:

Global Regenerative Wound Care Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Regenerative Wound Care Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type (Autologous Stem Cells, Biological Skin Substitutes, Tissue/Multiple Tissue Platform, Fetal Skin, Regenerative Wound Care Devices, Others)
    • 6.2.2. By Wound Type (Ulcers, Surgical & Traumatic Wounds, Burns)
    • 6.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Burn Care Centers & Wound Clinics, Others)
    • 6.2.4. By Region
    • 6.2.5. By Company (2024)
  • 6.3. Market Map

7. North America Regenerative Wound Care Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (Autologous Stem Cells, Biological Skin Substitutes, Tissue/Multiple Tissue Platform, Fetal Skin, Regenerative Wound Care Devices, Others)
    • 7.2.2. By Wound Type (Ulcers, Surgical & Traumatic Wounds, Burns)
    • 7.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Burn Care Centers & Wound Clinics, Others)
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Regenerative Wound Care Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Wound Type
        • 7.3.1.2.3. By End User
    • 7.3.2. Canada Regenerative Wound Care Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Wound Type
        • 7.3.2.2.3. By End User
    • 7.3.3. Mexico Regenerative Wound Care Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Wound Type
        • 7.3.3.2.3. By End User

8. Europe Regenerative Wound Care Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. B By Type (Autologous Stem Cells, Biological Skin Substitutes, Tissue/Multiple Tissue Platform, Fetal Skin, Regenerative Wound Care Devices, Others)
    • 8.2.2. By Wound Type (Ulcers, Surgical & Traumatic Wounds, Burns)
    • 8.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Burn Care Centers & Wound Clinics, Others)
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Regenerative Wound Care Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Wound Type
        • 8.3.1.2.3. By End User
    • 8.3.2. Germany Regenerative Wound Care Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Wound Type
        • 8.3.2.2.3. By End User
    • 8.3.3. United Kingdom Regenerative Wound Care Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Wound Type
        • 8.3.3.2.3. By End User
    • 8.3.4. Italy Regenerative Wound Care Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Wound Type
        • 8.3.4.2.3. By End User
    • 8.3.5. Spain Regenerative Wound Care Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Wound Type
        • 8.3.5.2.3. By End User

9. Asia-Pacific Regenerative Wound Care Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type (Autologous Stem Cells, Biological Skin Substitutes, Tissue/Multiple Tissue Platform, Fetal Skin, Regenerative Wound Care Devices, Others)
    • 9.2.2. By Wound Type (Ulcers, Surgical & Traumatic Wounds, Burns)
    • 9.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Burn Care Centers & Wound Clinics, Others)
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Regenerative Wound Care Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Wound Type
        • 9.3.1.2.3. By End User
    • 9.3.2. India Regenerative Wound Care Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Wound Type
        • 9.3.2.2.3. By End User
    • 9.3.3. Japan Regenerative Wound Care Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Wound Type
        • 9.3.3.2.3. By End User
    • 9.3.4. South Korea Regenerative Wound Care Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Type
        • 9.3.4.2.2. By Wound Type
        • 9.3.4.2.3. By End User
    • 9.3.5. Australia Regenerative Wound Care Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Type
        • 9.3.5.2.2. By Wound Type
        • 9.3.5.2.3. By End User

10. South America Regenerative Wound Care Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type (Autologous Stem Cells, Biological Skin Substitutes, Tissue/Multiple Tissue Platform, Fetal Skin, Regenerative Wound Care Devices, Others)
    • 10.2.2. By Wound Type (Ulcers, Surgical & Traumatic Wounds, Burns)
    • 10.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Burn Care Centers & Wound Clinics, Others)
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Regenerative Wound Care Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Wound Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Argentina Regenerative Wound Care Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Wound Type
        • 10.3.2.2.3. By End User
    • 10.3.3. Colombia Regenerative Wound Care Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Wound Type
        • 10.3.3.2.3. By End User

11. Middle East and Africa Regenerative Wound Care Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type (Autologous Stem Cells, Biological Skin Substitutes, Tissue/Multiple Tissue Platform, Fetal Skin, Regenerative Wound Care Devices, Others)
    • 11.2.2. By Wound Type (Ulcers, Surgical & Traumatic Wounds, Burns)
    • 11.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Burn Care Centers & Wound Clinics, Others)
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Regenerative Wound Care Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Wound Type
        • 11.3.1.2.3. By End User
    • 11.3.2. Saudi Arabia Regenerative Wound Care Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Wound Type
        • 11.3.2.2.3. By End User
    • 11.3.3. UAE Regenerative Wound Care Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Wound Type
        • 11.3.3.2.3. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products/Services

14. SWOT Analysis: Global Regenerative Wound Care Market

15. Competitive Landscape

  • 15.1. DeCell Technologies Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Avita Medical, Inc.
  • 15.3. Organogenesis, Inc.
  • 15.4. Histogen, Inc.
  • 15.5. RenovoDerm (Nanofiber Solutions, LLC)
  • 15.6. StemsysBio
  • 15.7. Koninklijke DSM N.V.
  • 15.8. MiMedx Group, Inc.
  • 15.9. 3M Company
  • 15.10. Smith & Nephew PLC

16. Strategic Recommendations

17. About Us & Disclaimer